Advancing β-Glucan-Based Immunomodulation and Nanotherapeutic Strategies for Cancer Biotherapy
Rattachement africain : in, sa. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
β-glucans are structurally diverse polysaccharides from fungi, yeasts, bacteria, and cereals, exhibiting variable branching and molecular weights that shape their biological activity. Emerging preclinical and clinical evidence highlights their ability to modulate innate and adaptive immunity, exerting direct and adjunct antitumor effects via dectin-1, toll-like receptors, and complement receptor 3. Although well known as nutraceuticals, their integration into advanced cancer biotherapeutics, such as monoclonal antibody regimens, cytokine modulation, and nanoparticle delivery, remains in early translation. This review examines the molecular basis of β-glucan-induced immunostimulation, emphasizing how linkage type, branching frequency, triple-helical structure, and source influence receptor engagement and downstream immune responses. Emerging evidence is presented on β-glucan formulation engineering, including β-glucan-coated polymeric nanoparticles and micelles, β-glucan-complexed lipid nanoparticles for nucleic acid delivery, polymersomes with splenic/myeloid avidity, and β-glucan-stabilized nanosuspensions, several of which show enhanced lymphatic targeting, improved drug bioavailability, or reduced tumor growth in preclinical cancer models. Clinical translation is analyzed with attention to dosing protocols, administration routes (oral, intravenous, topical), and the impact of β-glucan adjuvancy in therapeutic antibodies, immunotoxins, and vascular disrupting agents. The review further addresses essential safety and toxicology data, regulatory compliance challenges, and the imperative for rigorous physicochemical standardization to ensure clinical reproducibility and patient safety. β-glucans have emerged as multifunctional immunomodulators and drug delivery enhancers, driving progress toward personalized cancer immunotherapy and innovative combinatorial regimens. Continued interdisciplinary research and harmonization of extraction, characterization, and delivery protocols are paramount for success in precision oncology.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Advancing β-Glucan-Based Immunomodulation and Nanotherapeutic Strategies for Cancer Biotherapy
- Date Crossref
- 21/11/2025
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
REVA University REVA Research Center pays non établi dans la noticeUniversité ou école supérieure
-
Parul University pays non établi dans la noticeUniversité ou école supérieure
-
Chitkara University pays non établi dans la noticeUniversité ou école supérieure
-
Jouf University pays non établi dans la noticeUniversité ou école supérieure
-
Narsee Monjee Institute of Management Studies pays non établi dans la noticeUniversité ou école supérieure
-
School of Applied Sciences Department of Biotechnology pays non établi dans la noticeUniversité ou école supérieure
-
Chitkara College of Pharmacy Center for Research Impact and Outcome pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Pharmacy Department of Pharmaceutics pays non établi dans la noticeUniversité ou école supérieure
-
School of Pharmacy and Technology Management pays non établi dans la noticeUniversité ou école supérieure
REVA Research Center — REVA University, Parul University et Chitkara University, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.